The Brom Podcast

The Brom Podcast covers the emerging psychedelics industry from a business, investing and social impact perspective.  Episodes feature Empath's Founder, Brom Rector interviewing psychedelic CEOs, scientists, investors, and other change-makers operating in the weird, wonderful world of psychedelic medicine.

LISTEN ON
LISTEN ON
WATCH ON

All Episodes

Psychedelics, Connection and Sex with Dr. Molly Maloof
Selling Psilocybin Mushrooms Online with the Founder of Schedule35
Rebecca Nicholson - Investing in Psychedelic Retreats, Tripping with Amanda Feilding and the Importance of Female Representation in Psychedelics
Zach Haigney, Author of The Trip Report - Future Trends in the Psychedelics Industry
Sam Banister - The Art and Science of Designing Novel Psychedelic Compounds
Patrick Moher of Microdose.buzz - Psychedelics at Davos, Mike Tyson, and Wonderland Miami 2022
Music For Psychedelic Therapy - Mendel Kaelen, Founder and CEO of Wavepaths
Jesse Hudson - Making Kene Huaste mainstream and using Web3 to protect Indigenous Wisdom
Joe Moore, Co-Founder & CEO of Psychedelics Today - Hot Topics and Controversies in Psychedelics
Tom Feegel, CEO of Beond - Ending the Opiate Addiction Epidemic with Safe Ibogaine Treatment
Mycrodose Therapeutics Round 2: Kavalactones, Joint Venture with Thorne, Series A and more!
Dillan DiNardo - CEO of Mindstate Design Labs | Creating Novel Psychedelic States at Y Combinator
Juan Pablo Cappello - CEO of Nue Life
Quantified Citizen - Eesmyal Santos-Brault & Dr. Pamela Kryskow
Nadia van der Heyden - Psygen
10 Psychedelic Startup Ideas | Request for Psychedelic Startups
Mycrodose Therapeutics - Advanced Delivery Systems for Ketamine, Psilocybin and other Psychedelics
Todd Shapiro, CEO of Red Light Holland - Recreational Shrooms, Psychedelic VR & the Wisdom Truffle
Virtual Reality and the Future of Psychedelics - Lyle Maxson of Entheo Digital
Psychedelic Venture Capital - Interview with Ken Belotsky and Stuart Seidman of Negev Capital
How Mindbloom delivers Ketamine to your Door! Jack Swain on running a Psychedelics Startup
Paul Kohlhaas of Molecule & VitaDAO - how Crypto, NFTs, & DAOs can fund Longevity and Psychedelics
Bruce Linton on MindMed Insider Selling & JR Leaving + Stock Promotion in Psychedelics + RLHs Future
Ian McDonald & Gideon Shapiro of Bright Minds Bio. Is Psilocybin Dangerous? What is a 5HT2C Agonist?
Josh Bartch, CEO of Mydecine - Psilocybin for Smoking Cessation & PTSD, Nasdaq Uplisting and More!
Psychedelic Therapy FAQ - What is Psychedelic Therapy + 3 Most Compelling Psychedelic Studies | #15
Psychedelic Investing FAQ - An Overview of The Emerging Psychedelics Industry
Cybin CEO Doug Drysdale: Sublingual Psilocybin, Next-Gen Psychedelics & Brain Imaging Technology
JR & Bruce Linton Selling MindMed Shares - How I See It and What I Did
Interview: Ronan Levy of Field Trip Health - Psychedelic Clinics, Novel Molecules & Field Trip Stock
11: ATAI Life Sciences Deep Dive - IPO, Pipeline, Corporate Structure & Psilocybin Tattoos
Shroom Stock Research: 10 Questions to Ask Before Buying Psychedelic Stocks like MindMed and Compass
9: This Is Your Brain On MindMed - The Trading Psychology of Meme Stocks, Bubbles, Wins and Losses
8: Cybin Deep Dive - Psychedelics 2.0, a Real Pharma CEO, Twists on DMT, and Mushroom Supplements?
7: Compass Pathways Deep Dive - Patents, Peter Thiel and the Quest for Psychedelic Monopoly
6: Psychedelic Market Cap Projections - Napkin Math, Monte-Carlo and how Best to Invest
5: Numinus Wellness DeepDive. Sleeping Giant or Spread Too Thin?
4: MindMed Deep Dive PART 2 - HealthMode Acquisition and other follow-up
3: MindMed Deep Dive. JR Rahn, LSD, Nasdaq Uplisting, Pump and Dump or To the Moon?
2: the future of psychedelics
empath ventures logo
The Brom Podcast is brought to you by Empath Ventures